Maternal health and perinatal medicine are population health challenges which are in need of innovation. Preeclampsia and its sequela of eclampsia are among the most common reasons for maternal and perinatal morbidity, mortality and premature birth causing great human suffering and very high economic cost. Comanche is developing a novel treatment for preeclampsia with the goal of lowering the risks of poor birth outcomes, increasing the chances of the pregnancy reaching full term.
Location: United States, Massachusetts, Concord
Total raised: $75M
Investors 2
| Date | Name | Website |
| - | Population... | population... |
| - | F-Prime Ca... | fprimecapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.01.2024 | Series B | $75M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.01.2024 | Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia | - |
| 17.01.2024 | Comanche secures $75M to test preeclampsia siRNA in PhII, adds Scott Gottlieb to board | - |
| 28.10.2023 | The urgent call for innovation and investment in maternal health | Maneesh Jain Contributor Share on X Maneesh Jain, PhD, is CEO and co-founder of Mirvie, a company pioneering the prediction of life-threatening pregnancy complications months in advance. More than 500 years ago, Leonardo da Vinci became fas... |
| 21.10.2022 | Explore how Breakthroughs in Biology are Improving Treatment of Preeclampsia | JUPITER, Fla. (PRWEB) October 21, 2022 On an upcoming segment of Advancements with Ted Danson, audiences will learn about the latest developments in novel siRNA therapies for treatment of preeclampsia. The show will educate about preeclamps... |
| - | Comanche Biopharma | “Comanche Biopharma” |